Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025.
As more companies moved to Oak Ridge, 2024 brought with it a steady stream of nuclear news coming out of the Knoxville region ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback